Lanperisone (NK433) is muscle relaxant. It acts by blocking voltage-gated sodium channels.

ZK 200775, also known as fanapanel, an antagonist at the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor, possesses neuroprotective efficacy in patients with acute ischemic stroke. However, the phase II of clinical trials had revealed, that this compound had led to the neuronal dysfunction and the glial cell toxicity had occurred. In addition, was shown, that the antagonization of AMPA receptors by ZK200775 lead to alterations of color and dark vision, visual acuity, cone electroretinogram (ERG) modalities and the pattern-reversal visual evoked potentials and to a lesser extent on the scotopic ERG. At the same time, ZK 200775 did not alter eye morphology, the functioning of the extraocular muscles, binocular vision, visual fields or the pupil.

Pelrinone, a cardiotonic drug, is a phosphodiesterase III inhibitor that was studied in clinical trials phase II for the treatment of patients with heart failure.

Dexindoprofen is a non-steroidal drug that has analgesic and anti-inflammatory properties. Dexindoprofen is the dextrorotatory stereo-isomer of indoprofen, to which it has a similar adverse effect pattern. Gastrointestinal and nervous system effects and skin reactions are the most frequent. Following reports of severe gastrointestinal bleeding and carcinogenicity in animals indoprofen was withdrawn from the market worldwide.

There is no information about pharmacological and biological properties of epicainide. It is known, that drug was a potent antiarrhythmic agent.

Metesind (AG-331) is a lipophilic thymidylate synthase inhibitor. It inhibits the cofactor binding site of the enzyme. It exerts cytotoxic properties. Metesind was being developed as an anticancer and antimetabolite agent.

Cefcanel is a semisynthetic third-generation cephalosporin with antibacterial activity. Cefcanel is active against the species E. coli, K. aerogenes and Proteus mirabilis; H. influenzae and M. catarrhalis has reasonable susceptibility. Cefcanel inhibits 90% of S. aureus strains at 2 µg/ml, irrespective of the presence of a β-lactamase. Cefcanel binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.

Meseclazone (W-2395) is a non-steroidal anti-inflammatory drug. It exerts anti-inflammatory, analgesic and antipyretic activity. Meseclazone inhibits in vitro and ex vivo platelet aggregation initiated by the release reaction. It inhibits bradykinin-induced bronchospasm.